Global & Cross-Border Intellectual Property

We are consistently recognized among the top practitioners in intellectual property transactions and licensing, with honors reflecting our impact on high-value collaborations and strategic transactions.

• Chambers USA – Intellectual Property
• Chambers Global China – Intellectual Property (International Firms) (Expertise Based Abroad)
• LMG Life Sciences EMEA Awards “Impact Deal – Servier: Black Diamond Therapeutics BDTX-4933 Licensing Agreement” (2026)
• The Legal 500 US – Intellectual Property
• The Legal 500: US, Greater China, UK – Life Sciences and Healthcare - Foreign Firms
• IAM Patent 1000: The World's Leading Patent Practitioners (2019-2026)
• The American Lawyer “Corporate Practice of the Year – Pharma and Health Care” (2022, 2024)
• Managing Intellectual Property “Patent Star China” (2018, 2022)
• IAM Global Leaders: The World’s Leading IP Strategists (2012-2017, 2022, 2026)

We regularly manage multi-jurisdictional intellectual property matters, coordinating cross-border licensing programs, international joint ventures, and global IP portfolio strategies for clients operating across diverse regulatory environments.

• Adaptimmune in its $3+ billion strategic collaboration with Genentech to research, develop and commercialize cancer-target allogeneic T-cell therapies, under which the companies will combine their technologies and expertise to research and develop “off-the-shelf” cell therapies for up to five cancer targets and develop a novel allogeneic personalized cell therapy platform.
• Adicon Holdings in a strategic partnership with Guardant Health to provide comprehensive genomic profiling (CGP) in mainland China.
• Akebia Therapeutics in the $865 million global expansion of its collaboration with Otsuka Pharmaceutical covering Europe, China, and other territories.
• Allorion Therapeutics in a global licensing agreement with Avenzo Therapeutics for AVZO-021 (CDK2 inhibitor), excluding Greater China, in a transaction exceeding $1 billion.
• Apollo Therapeutics in a licensing agreement with Sunshine Lake Pharma (HEC Group), granting Apollo exclusive ex-China rights to a clinical-stage FGF21/GLP-1 dual receptor agonist.
• Assembly Biosciences in a license and collaboration agreement with BeiGene for HBV core inhibitor programs in China.
• Bain Capital in a $1.05 billion license and collaboration between One Bio and Jiangsu Hengrui Pharmaceuticals to develop and commercialize SHR-1905 globally (excluding Greater China).
• Black Diamond Therapeutics, headquartered in France, in a global licensing agreement with Servier for the development and commercialization of BDTX-4933, a therapy designed to target RAS and RAF alterations in solid tumors.
• Blueprint Medicines in an exclusive collaboration with CStone Pharmaceuticals for development and commercialization of multiple oncology programs in Greater China.
• CANbridge Pharmaceuticals in multiple transactions, including:
  • exclusive license with Mirum Pharmaceuticals for maralixibat in Greater China.
  • termination and restructuring of prior licensing arrangements.
  • sponsored research agreements with leading academic institutions.
• CASI Pharmaceuticals in multiple licensing and collaboration transactions, including:
  • in-licensing oncology and pipeline assets from Spectrum Pharmaceuticals for China.
  • exclusive China immuno-oncology licensing with BioInvent International.
  • licensing agreement with Cleave Therapeutics for CB-5339 in Greater China.
• Coherus BioSciences in a $1.1 billion cross-border collaboration with Junshi Biosciences for toripalimab development and commercialization in North America.
• CStone Pharmaceuticals:
  • in a global strategic partnership with biotech EQRx to out-license two late-stage immune checkpoint inhibitor therapies for development and commercialization outside of Greater China. CStone will receive an upfront payment of $150 million and up to $1.15 billion in milestone payments for both therapies as well as separate tiered royalties.
  • in a license agreement with South Korea-based LegoChem Biosciences for development and commercialization of a new antibody drug conjugate with applications for multiple solid and hematological cancers.
• Eli Lilly in digital health collaborations with Tencent and DXY to develop and launch an integrated diabetes patient care platform in China.
• Erasca, Inc. in an exclusive license for a pre-clinical pan-RAS molecular glue program (ERAS-0015) targeting RAS mutations in oncology.
• Everest Medicines in multiple cross-border agreements, including:
  • collaboration with Kezar Life Sciences on zetomipzomib.
  • in-license of sacituzumab govitecan (ADC).
  • mRNA technology transfer and collaboration partnership.
  • collaboration with BeiGene and other global biotech partners.
• HilleVax in an exclusive license with Chengdu Kanghua Biological Products for a hexavalent VLP norovirus vaccine outside Greater China.
• Innovent Biologics in multiple cross-border collaborations, including:
  • multi-program oncology collaboration with Eli Lilly.
  • collaboration and license agreements with Incyte.
  • collaborations with Coherus and Eli Lilly on metabolic and immuno-oncology programs.
• Ionis Pharmaceuticals in a license agreement with Otsuka Pharmaceutical granting exclusive Asia-Pacific rights to donidalorsen for hereditary angioedema.
• iTeos Therapeutics, a Belgian biopharmaceutical company, in a $2 billion collaboration with global health care leader GSK to co-develop and co-commercialize an anti-TIGIT monoclonal antibody as a potential treatment for cancer patients.
• Kailera Therapeutics, Inc. and its investors in the formation of the company, $400 million Series A financing, and worldwide (ex-China) licensing of a portfolio of clinical-stage metabolic disease assets from Jiangsu Hengrui Pharmaceuticals.
• Kiniksa Pharmaceuticals:
  • in a multi-million dollar global license agreement with Roche and Genentech directed towards the development and commercialization of vixarelimab, a potential treatment for fibrosis.
  • in a $662 million collaboration with Huadong for autoimmune and inflammatory disease programs in Greater China and broader Asia-Pacific.
• Lepu Biopharma in a $1.6 billion exclusive license agreement with ArriVent BioPharma for novel antibody-drug conjugate (ADC) MRG007, in development for gastrointestinal cancers.
• Mammoth Biosciences in a collaboration and license agreement with Regeneron Pharmaceuticals for CRISPR/Cas gene editing therapies targeting Regeneron-selected programs.
• NetEase in its exclusive license from Mojang for the development and commercialization of Minecraft in China.
• Novo Nordisk in an exclusive global license with The United Laboratories for UBT-251 (triple agonist) across global markets excluding Greater China.
• Paratek Pharmaceuticals in collaboration with Zai Lab for development and commercialization of omadacycline in China.
• Pediatrix Therapeutics in multiple China-focused collaborations, including expanded exclusive commercialization rights to Tris Pharma's ADHD portfolio in China.
• Pfizer:
  • in a strategic global licensing and collaboration agreement with China-based Innovent Biologics for the research and development of 12 innovative cancer medicines worth up to $10.5 billion.
  • in connection with its $1.24 billion ex-U.S. strategic collaboration with Biohaven to commercialize rimegepant.
• R1 Therapeutics in an exclusive global license from Alebund Pharmaceuticals (China) to develop and commercialize AP306 outside Greater China for hyperphosphatemia in chronic kidney disease patients on dialysis.
• Revolution Medicines in a multi-part collaboration with BeOne Medicines, granting BeOne exclusive development and commercialization rights in select Asian markets, including Japan and South Korea.
• Sanofi in an exclusive worldwide collaboration with Skyhawk Therapeutics for up to more than $2 billion to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology disease targets with limited or no therapeutic options.
• Simcere Pharmaceutical Group in a strategic collaboration with Merus (Netherlands) for exclusive China rights to three bispecific antibodies using Biclonics® technology.
• SK Biopharmaceuticals:
  • in a global licensing agreement (up to $571.5 million) with Full-Life Technologies for worldwide development, manufacturing, and commercialization rights to FL-091 radiopharmaceutical.
  • in a research and development collaboration with Insilico Medicine to discover AI-enabled drug candidates in neuroimmune disorders of the central nervous system in a deal worth up to $2.5 billion.
• Tanabe Pharma Corporation in entering an agreement to sell dersimelagon, an oral therapy designed to increase pain-free sunlight exposure, to LEO Pharma.
• Tenacia Biotechnology:
  • in a strategic collaboration with Rapport Therapeutics granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China.
  • in an exclusive collaboration with Praxis Precision Medicines to develop and commercialize ulixacaltamide in Greater China for essential tremor.
• Viela Bio in the out-licensing of its anti-CD19 monoclonal antibody to Hansoh (China).
• Zai Lab in multiple cross-border collaborations and in-licensing transactions, including:
• A biopharmaceutical company in an AI-enabled research collaboration worth up to $5.3 billion with a China-based pharmaceutical group to advance the discovery and development of novel oral drug candidates across multiple disease indications.